The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you ...

One lot of reflux medicine got recalled when fluid retention tablets were discovered in the medicine bottles.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the ...

Today, Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) announced the launch of a technological innovation program in drug development, at an investment expected to reach tens of millions of ...

Despite the popularity of generic and biosimilar drugs in Europe—the latter of which have struggled to catch on in the ...

Billionaire investment legend Stanley Druckenmiller is quickly becoming one of my favorite big-money managers to follow ...

Teva Pharmaceutical Industries (NYSE:TEVA) Upsizes Senior Notes Offering to US$2.3 Billion Teva Pharmaceutical Industries (NYSE:TEVA) recently made headlines by upsizing its senior notes offering to ...

Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company ...

Opinion: Orrick's Irena Royzman and Dana Sublett write that judges have done a good job in multiple decisions that protect ...

Final results from the Phase IV PEARL trial show that 66% of patients treated with Ajovy for episodic migraine and more than ...

Teva pharmaceuticals has issued a voluntary recall of one lot of its reflux medication after discovering that bottles contained tablets of a drug used to treat fluid retention. The recall affects lot ...